drugset / Trial / NCT00351195
Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
Phase 2
Terminated
39 enrolled
Rigshospitalet, Denmark
Morten Ladekarl, MD, DMSc., Dept. of Oncology, Århus Sygehus, Århus · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Various cytotoxic agents have been evaluated in advanced hepatocellular carcinoma, but response rates have been low with significant toxicity, most often due to parenchymal liver disease. The three agents etoposide, oxaliplatin and capecitabine each has sparse efficacy as single agents, but the combination may act synergistically with an acceptable toxicity profile.
Timeline
- Start
- 2006-02
- Primary completion
- —
- Completion
- 2007-04
Outcome
Outcome not reported
Stopped: “Did not meet the criteria for continuation to second stage”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Etoposide | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |